Table 2.
Indications for WCD usage across the included articles
| Study name | Number of patients |
Secondary prevention |
ICD Explant | ICM | NICM | NICM Subgroups | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Idiopathic /DCM | PPCM | Myocarditis | TCM | Others | ||||||
| Olgin 2018 | 1524 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wäßnig 2016 | 6043 | NR | 11.9% | 26.9% | 61.2% | 79.8% | 0.0% | 16.1% | 0.0% | 4.1% |
| Zishiri 2012 | 809 | NR | 0.0% | 100% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Epstein 2013 | 8453 | NR | 0.0% | 100% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Chung 2010 | 2731 | 16.0% | 23.4% | 25.2% | 35.4% | 79.5% | NR | NR | NR | 20.5% |
| Ellenbogen 2017 | 8058 | NR | 100% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Barraud 2017 | 24 | NR | 0.0% | 100% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Leyton-Mange 2017 | 147 | 21.8% | 23.1% | 22.4% | 32.7 | 77.1% | NR | 2.1% | 0.0% | 20.8% |
| Kao 2012 | 80 | NR | 0.0% | 36.3% | 63.7% | 60.8% | 2.0% | 4.0% | NR | 33.2% |
| Lamichhane 2016 | 220 | NR | 0.0% | 35.5% | 64.5% | 95.8% | NR | NR | NR | 4.2% |
| Bhaskaran 2015 | 8 | 0.0% | 37.5% | 0.0% | 62.5% | 40.0% | 20.0% | 20.0% | 0.0% | 20.0% |
| Barsheshet 2017 | 75 | NR | NR | 33.3% | 66.7% | NR | NR | NR | NR | NR |
| Beiert 2017 | 114 | NR | 11.4% | 31.6% | 57.0% | 80.0% | NR | NR | NR | 20.0% |
| Naniwadekar 2017 | 140 | 9.0% | 8.0% | 32.0% | 51.0% | 90.1% | NR | NR | NR | 9.9% |
| Kondo 2015 | 24 | 54.2% | 0.0% | 45.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Erath 2017 | 130 | NR | 0.0% | 35.4% | 64.6% | 54.8% | NR | 11.9% | 22.6% | 10.7% |
| Feldman 2003 | 289 | NR | NR | 39% | Unclear† | NR | NR | NR | NR | NR |
| Tanawuttiwat 2014 | 97 | NR | 100% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Quast 2017 | 79 | NR | 41.8% | 15.2% | 43.0% | NR | NR | NR | NR | NR |
| Duncker 2017 | 117 | NR | 0.0% | 0.0% | 100.0% | 77.8% | 17.1% | 5.1% | 0.0% | 0.0% |
| Singh 2015 | 525 | NR | 0.0% | 51.6% | 48.4% | 81.4% | 0.4% | 0.0% | 15.4% | 2.8% |
| Sasaki 2016 | 50 | 76.0% | 0.0% | 12.0% | 12.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Salehi 2016 | 127 | NR | 0.0% | 0.0% | 100% | 100% | 0.0% | 0.0% | 0.0% | 0.0% |
| Erath 2017 | 102 | NR | 24.5% | 26.5% | 49.0% | 66.0% | 4.0% | 18.0% | 0.0% | 12.0% |
| Opreanu 2015 | 121 | NR | 0.0% | 17.4% | 82.6% | 67.0% | 0.0% | 0.0% | 0.0% | 33.0% |
| Saltzberg 2012 | 266 | 0.0% | 0.0% | 0.0% | 100% | 59.8% | 40.2% | 0.0% | 0.0% | 0.0% |
| Kutyifa 2015 | 2000 | NR | NR | 40.0% | 60.0% | 77.6% | NR | NR | NR | 22.4% |
| Duncker 2017 | 49 | 0.0% | 0.0% | 0.0% | 100% | 0.0% | 100% | 0.0% | 0.0% | 0.0% |
*
NICM: Non-ischemic cardiomyopathy; ICM: Ischemic cardiomyopathy; PPCM: Peripartum cardiomyopathy; DCM: dilated cardiomyopathy; TCM: tachycardia-induced cardiomyopathy; ICD: implantable cardioverter defibrillator; NR: not reported
†
It is unclear if the 61% of subjects with heart failure in the WEARIT sub-study had non-ischemic cardiomyopathy.